Available Until 2/8/2025

Office Hours Roundtable: Enhancing Care for Special Patient Populations in the Shadow of the COVID-19 Pandemic

Content Release Date: April 23, 2024
Expiration Date: February 8, 2025
CE Credits: There is no CE credit with this activity
Activity Fee: Free

Activity Overview

This office hours session with expert faculty follows a 1.5 hour symposium/live webinar entitled: COVID-19 Now and Beyond: Where Do We Go From Here? This initiative provides a background on the pharmacist’s role in current COVID-19 prevention and treatment, including special patient populations; a review of new and emerging therapies; and potential implications of coverage and access to COVID-19 vaccines, therapies, and tests.

No formal presentation was planned for this session. Attendees submitted question(s) for the faculty experts.

More in this Series:

Engaging the Experts PodcastsCOVID-19: So What’s New?

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity was planned to meet the educational needs of pharmacists who practice in hospitals and health systems.

How It Works:

Questions pre-submitted during registration were addressed before live questions, in the order they were received.

During the session, questions were submitted via the chat.

Katherine Yang, PharmD, MPH, FCSHP
Co-Vice Dean, Clinical Innovation and Entrepreneurship and Professor
UCSF School of Pharmacy
Infectious Diseases Clinical Pharmacist
UCSF Medical Center
San Francisco, California

Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the UCSF School of Pharmacy and an infectious diseases clinical pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the pharmacokinetic and pharmacodynamic optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics. 

Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP
Clinical Pharmacy Specialist, Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Monica Mahoney, PharmD, BCPS, BCIDP, FCCP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, and the Infectious Diseases Society of America.


Sarah Parsons, PharmD, BCPPS
Clinical Pharmacy Specialist, Pediatric
Infectious Diseases, Antimicrobial Stewardship Co Lead
The Children's Hospital of the King's Daughters
Norfolk, Virginia

Sarah Parsons, PharmD, BCPPS is a clinical pharmacy specialist in pediatric infectious diseases at the Children’s Hospital of the King’s Daughters focusing in antimicrobial stewardship and COVID-19 management in pediatric patients. Dr. Parsons received her Bachelor of Science focused in microbiology and immunology from Radford University followed by her Doctor of Pharmacy Degree from Virginia Commonwealth School of Pharmacy. She completed a postgraduate year 1 residency at HCA Health system in Richmond, Virginia.

Michael Ganio, PharmD, MS, BCPS, FASHP
Senior Director, Pharmacy Practice and Quality
Bethesda, Maryland

Michael Ganio, PharmD, MS, BCPS, FASHP joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Certified Professional in Healthcare Information and Management Systems (CPHIMS).

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

  •          Monica V. Mahoney: BD Bioscience – Consultant, Speaker’s bureau, GSK – Consultant , Cidara – Consultant, Pfizer – Consultant

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Provided by ASHP.
Supported by an educational grant from AstraZeneca.